Review
Pharmacology & Pharmacy
Xiaoyu Qian, Xiaodan Guo, Ting Li, Wei Hu, Lin Zhang, Caisheng Wu, Feng Ye
Summary: ICI monotherapy did not improve the overall survival (OS) or progression-free survival (PFS) of patients with EGFR-TKI-resistant NSCLC. However, ICI-based combination therapy showed better PFS and objective response rate (ORR) compared to conventional chemotherapy.
FRONTIERS IN PHARMACOLOGY
(2022)
Review
Oncology
Daisy Wai-Ka Chan, Horace Cheuk-Wai Choi, Victor Ho-Fun Lee
Summary: This study conducted a systematic review and meta-analysis to investigate the treatment-related adverse events (trAEs) of combined epidermal growth factor tyrosine kinase inhibitor (EGFR-TKI) and immune checkpoint inhibitor (ICI) in advanced non-small cell lung cancer (NSCLC). The results demonstrated a higher incidence of grade >= 3 trAEs in combination TKI and ICI, particularly in skin, gastrointestinal tract, and interstitial lung diseases. However, the interpretation of these results should be cautious due to the limited number of studies included in this meta-analysis.
Article
Immunology
Shujie Zhou, Fei Ren, Xiangjiao Meng
Summary: This study evaluated the efficacy of immune checkpoint inhibitor (ICI) therapy in EGFR-mutant non-small cell lung cancer (NSCLC) patients with brain metastases (BMs). Results showed that ICI combined with chemotherapy had potent intracranial efficacy and may be a promising treatment candidate for these patients.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Pharmacology & Pharmacy
Shui Liu, Shuai Geng, Ning Shi, Lili Zhang, Wenxin Xue, Yiwen Li, Kai Jiang
Summary: The study aimed to investigate the impact of single gene mutation status of KRAS, EGFR, and TP53 on the therapeutic effect of ICIs in cancer patients. The results showed that single gene mutation of KRAS, EGFR, or TP53 could significantly improve the progression-free survival (PFS) and overall survival (OS) in patients receiving ICIs, but the degree of improvement varied.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Immunology
Qian Chen, Xiaoling Shang, Ni Liu, Xinchun Ma, Wenfei Han, Xiuwen Wang, Yanguo Liu
Summary: The study found that patients with major EGFR mutations had poorer responses to ICIs compared to patients with rare EGFR mutations. EGFR-mutated patients with lower PD-L1 expression tended to have longer overall survival after receiving ICIs. Heavily treated patients with more than three prior lines of therapy had significantly shorter progression-free survival and overall survival, as well as a lower objective response rate.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Patrick T. Magahis, Steven B. Maron, Darren Cowzer, Stephanie King, Mark Schattner, Yelena Janjigian, David Faleck, Monika Laszkowska
Summary: This study found an association between H. pylori infection and inferior survival in patients with gastric cancer treated with immune checkpoint inhibitors.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Oncology
Wei Mu, Evangelia Katsoulakis, Christopher J. Whelan, Kenneth L. Gage, Matthew B. Schabath, Robert J. Gillies
Summary: The study used radiomics analysis of PET/CT images to predict cachexia risk in NSCLC patients treated with ICI, and found that the radiomics signature could also help predict durable clinical benefit, progression-free survival, and overall survival following ICI treatment.
BRITISH JOURNAL OF CANCER
(2021)
Review
Oncology
Qiang Wu, Wuxia Luo, Wen Li, Ting Wang, Lin Huang, Feng Xu
Summary: This meta-analysis indicated that the combination of first-generation EGFR-TKI and CT significantly improves objective response rate (ORR) and prolongs progress-free survival (PFS) and overall survival (OS) in patients with advanced EGFR-mutated NSCLC, compared to EGFR-TKI monotherapy. Despite the increased incidence of chemotherapy-induced toxicities in the combination group, it is well tolerated and clinically manageable.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Jan Budczies, Martina Kirchner, Klaus Kluck, Daniel Kazdal, Julia Glade, Michael Allgaeuer, Mark Kriegsmann, Claus-Peter Heussel, Felix J. Herth, Hauke Winter, Michael Meister, Thomas Muley, Torsten Goldmann, Stefan Froehling, Martin Wermke, Cornelius F. Waller, Amanda Tufman, Martin Reck, Solange Peters, Peter Schirmacher, Michael Thomas, Petros Christopoulos, Albrecht Stenzinger
Summary: The study found specific immunosuppressive characteristics in ALK- and EGFR-positive lung adenocarcinoma, supporting further clinical evaluation of immune-modulators as partners of immune checkpoint blockade in such tumors. The targeted gene expression profiling is a promising tool to analyze tumor microenvironment characteristics from routine diagnostic lung cancer biopsies.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2022)
Article
Oncology
Julia Rotow, Jyoti D. Patel, Matthew P. Hanley, Helena Yu, Mark Awad, Jonathan W. Goldman, Hovav Nechushtan, Matthias Schef, Chih-Hsi S. Kuo, Senthil Rajappa, Guilherme Harada, Sarah Clifford, Alison Santucci, Laura Silva, Rebecca Tupper, Geoffrey R. Oxnard, Jennifer Kherani, Alexander Drilon
Summary: This study found that the combination of osimertinib and selpercatinib can be effective in treating EGFR-mutant NSCLC with acquired RET fusions as a mechanism of EGFR inhibitor resistance. It supports the need for further evaluation of this combination therapy in prospective studies.
CLINICAL CANCER RESEARCH
(2023)
Article
Medicine, General & Internal
Jeng-Shiuan Tsai, Po-Lan Su, Szu-Chun Yang, Chao-Chun Chang, Chia-Ying Lin, Yi-Ting Yen, Yau-Lin Tseng, Wu-Wei Lai, Chien-Chung Lin, Wu-Chou Su
Summary: Real-world data analysis demonstrates that the combination of EGFR-TKI and bevacizumab improves progression-free survival (PFS) in patients with EGFR-mutant non-small cell lung cancer, with better overall survival (OS) observed in patients harboring the L858R mutation.
JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION
(2021)
Review
Oncology
Marco Tagliamento, Paolo Bironzo, Hubert Curcio, Emmanuele De Luca, Daniele Pignataro, Simonetta G. Rapetti, Marco Audisio, Valentina Bertaglia, Chiara Paratore, Maristella Bungaro, Emanuela Olmetto, Elisa Artusio, Maria Lucia Reale, Clizia Zichi, Enrica Capelletto, Simona Carnio, Lucio Buffoni, Francesco Passiglia, Silvia Novello, Giorgio Vittorio Scagliott, Massimo Di Mai
Summary: Research has shown that anti-PD-1/PD-L1 immune checkpoint inhibitors (ICIs) may be a treatment option for chemotherapy-resistant asMM, although reliable predictive factors are currently lacking.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
(2022)
Article
Multidisciplinary Sciences
Kenichi Koyama, Satoru Miura, Satoshi Watanabe, Satoshi Shoji, Jun Koshio, Yoshiki Hayashi, Daisuke Ishikawa, Ko Sato, Takao Miyabayashi, Masaaki Okajima, Takeshi Ota, Tomohiro Tanaka, Naoya Matsumoto, Hideyuki Kuriyama, Tetsuya Abe, Koichiro Nozaki, Kosuke Ichikawa, Rie Kondo, Hiroshi Tanaka, Toshiaki Kikuchi
Summary: Rebiopsy is crucial in selecting optimal treatments for NSCLC patients with acquired resistance mutations, with a high implementation rate of 90.8% observed in Japanese clinical practice. Obtaining histological or cytological tissue samples during rebiopsy may contribute to improving the detection rate of the T790M mutation.
SCIENTIFIC REPORTS
(2022)
Article
Oncology
Weiguang Gu, Hua Zhang, Yiyu Lu, Minjing Li, Shuang Yang, Jianmiao Liang, Zhijian Ye, Zhihua Li, Minhong He, Xiaoliang Shi, Fei Wang, Dong You, Weiquan Gu, Weineng Feng
Summary: In this multicenter clinical trial in China, we investigated the efficacy of adding pemetrexed to improve progression-free survival (PFS) in epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) patients. There were no significant differences in PFS between patients with or without concomitant alterations, or between patients receiving EGFR-tyrosine kinase inhibitor (TKI) monotherapy or combined with pemetrexed. However, stratification analysis revealed that TKI monotherapy showed better PFS in non-concomitant group, while TKI combined with pemetrexed showed better PFS in concomitant group. Molecular dynamic analysis supported the better efficacy of TKI combined chemotherapy compared to TKI monotherapy. Additionally, circulating tumor DNA (ctDNA) minimal residual disease (MRD) showed potential as a biomarker for predicting therapeutic efficacy.
CANCER RESEARCH AND TREATMENT
(2023)
Review
Medicine, General & Internal
Dahui Yu, Chong Yuan, Hedan Zhang, Wenyan Chu
Summary: This meta-analysis assessed the relationship between tumor mutation burden (TMB) and the efficacy of PD-1/PD-L1 inhibitors in advanced non-small cell lung cancer (NSCLC) patients. The findings suggest that NSCLC patients with high TMB may benefit from immunotherapy, although TMB failed to predict overall survival benefits.